Search results for "RELATIONSHIP"

showing 10 items of 3616 documents

Synthesis and biological activities of a new class of heat shock protein 90 inhibitors, designed by energy-based pharmacophore virtual screening

2013

The design through energy-based pharmacophore virtual screening has led to aminocyanopyridine derivatives as efficacious new inhibitors of Hsp90. The synthesized compounds showed a good affinity for the Hsp90 ATP binding site in the competitive binding assay. Moreover, they showed an excellent antiproliferative activity against a large number of human tumor cell lines. Further biological studies on the derivative with the higher EC50 confirmed its specific influence on the cellular pathways involving Hsp90.

AminopyridinesInhibitory Concentration 50Structure-Activity RelationshipUser-Computer InterfaceHeat shock proteinCell Line TumorSettore BIO/10 - BiochimicaDrug DiscoveryHumansHSP90 Heat-Shock ProteinsBinding siteVirtual screeningheat shock protein 90 inhibitors energy-based pharmacophore virtual screening cell cycle antiproliferative activitybiologyChemistryHsp90Combinatorial chemistrySettore CHIM/08 - Chimica FarmaceuticaHuman tumorMolecular Docking SimulationCell cultureDrug DesignEnergy basedbiology.proteinMolecular MedicinePharmacophoreDrug Screening Assays Antitumor
researchProduct

Effects of amsacrine (m-AMSA), a new aminoacridine antitumor drug, on the rabbit heart.

1983

There is emerging clinical evidence that amsacrine (m-AMSA) administration may be associated with cardiotoxic effects such as severe, even fatal, ventricular arrhythmias and impairment of the inotropic performance of the heart. Information on the cardiac effects of m-AMSA in animals is scanty. Studies on mice, dogs, and monkeys have not evidenced the cardiotoxicity of the compound. The data presented in this paper show that m-AMSA causes acute ECG alterations in normal rabbits and a dose-related negative inotropic effect on the isolated rabbit heart, suggesting that this species may be a useful model for the study of the cardiac actions of this antiblastic.

AmsacrineDose-Response Relationship DrugAminoacridinesHeart VentriclesAntineoplastic AgentsArrhythmias CardiacHeartModels BiologicalMyocardial ContractionCardiotoxicityElectrocardiographym-Amsaantitumor drugDepression ChemicalHeart Function Testscancer.AnimalsRabbitsCancer treatment reports
researchProduct

Time trials versus time-to-exhaustion tests: Effects on critical power, W0, and oxygen-uptake kinetics

2018

Purpose: To investigate single-day time-to-exhaustion (TTE) and time-trial (TT) -based laboratory tests values of critical power (CP), W prime (W0), and respective oxygen-uptake-kinetic responses. Methods: Twelve cyclists performed a maximal ramp test followed by 3 TTE and 3 TT efforts interspersed by 60 min recovery between efforts. Oxygen uptake (VO 2) was measured during all trials. The mean response time was calculated as a description of the overall VO 2-kinetic response from the onset to 2 min of exercise. Results: TTE-determined CP was 279 ± 52 W, and TT-determined CP was 276 ± 50 W (P = .237). Values of W0 were 14.3 ± 3.4 kJ (TTE W0) and 16.5 ± 4.2 kJ (TT W0) (P = .028). While a hig…

Anaerobic work capacityVO 2 responsePower–duration relationshipSevere-intensity exercise
researchProduct

Topological Approach to Analgesia

1994

AnalgesicsTheoretical computer scienceChemical PhenomenaMolecular StructureChemistry PhysicalComputer sciencebusiness.industryGeneral ChemistryComputer Science ApplicationsStructure-Activity RelationshipText miningModels ChemicalComputational Theory and MathematicsDrug DesignAnimalsbusinessInformation SystemsJournal of Chemical Information and Computer Sciences
researchProduct

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

2015

Abstract The objective of this paper is to apply a previously developed semi-physiologic pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials (BE) of acetyl salicylic acid (ASA) in order to validate the model performance against ASA human experimental data. ASA is a drug with first-pass hepatic and intestinal metabolism following Michaelis–Menten kinetics that leads to the formation of two main metabolites in two generations (first and second generation metabolites). The first aim was to adapt the semi-physiological model for ASA in NOMMEN using ASA pharmacokinetic parameters from literature, showing its sequential metabolism. The second aim was to validate this mod…

AnalyteChemistry PharmaceuticalMetaboliteCmaxPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalBiomarkers PharmacologicalFirst pass effectchemistry.chemical_compoundPharmacokineticsIn vivoHumansMedicineComputer SimulationTissue DistributionBiotransformationChromatographyAspirinDose-Response Relationship Drugbusiness.industryHippuratesAnti-Inflammatory Agents Non-SteroidalNONMEMDrug LiberationTherapeutic EquivalencychemistryPharmacology ClinicalSalicylic AcidbusinessAlgorithmsSoftwareEuropean Journal of Pharmaceutical Sciences
researchProduct

Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium

2001

Background—Complement activation during reperfusion of ischemic myocardium augments myocardial injury, and complement inhibition with C1-esterase inhibitor (C1-INH) at the time of reperfusion exerts marked cardioprotective effects in experimental studies. Application of C1-INH in newborns, however, was recently reported to have dangerous and even lethal side effects. This study addresses the essential role of dosage in studies using C1-INH.Methods and Results—Cardioprotection by C1-INH was examined in a pig model with 60 minutes of coronary occlusion followed by 120 minutes of reperfusion. C1-INH was administered intravenously 5 to 10 minutes before coronary reperfusion without heparin at a…

Anaphylatoxinsmedicine.medical_specialtyNecrosisSwineHeart VentriclesPartial PressureMyocardial IschemiaIschemiaComplement C1 Inactivator ProteinsPharmacologyNecrosisTroponin TCoronary CirculationPhysiology (medical)Internal medicineAnimalsMedicineLactic AcidMyocardial infarctionCardiac OutputCreatine KinaseCardioprotectionDose-Response Relationship Drugbiologybusiness.industryMyocardiumHemodynamicsHeparinmedicine.diseaseComplement systemOxygenMicroscopy ElectronEndocrinologyCoronary occlusionEnzyme inhibitorReperfusion Injurybiology.proteinBlood Gas Analysismedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Adaptogens in chemobrain (Part II): Effect of plant extracts on chemotherapy-induced cytotoxicity in neuroglia cells

2019

Abstract Background Cancer chemotherapy-induced cognitive impairments are apparently associated with harmful effects on physiological functions of brain cells. Adaptogens, are known to exhibit neuroprotective effects and to increase cognitive functions in clinical studies. In our previous study (Seo et al., 2018), we demonstrated that selected adaptogenic extracts significantly attenuate cytostatic-induced regulation of more than 100 genes involved in the activation of neuronal death and inhibiting neurogenesis. Neuroprotective and cytoprotective activities of adaptogens rise the question about their possible impact on cytostatic effects of a chemotherapeutic combination of 5-fluorouracil, …

AndrographolidePharmaceutical ScienceEleutherococcusPharmacologyNeuroprotectionCell Linelaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawAntineoplastic Combined Chemotherapy ProtocolsDrug DiscoveryRhodiolamedicineHumansCytotoxic T cellCytotoxicityCyclophosphamideEpirubicin030304 developmental biologyPharmacology0303 health sciencesDose-Response Relationship DrugbiologyPlant ExtractsNeurotoxicitybiology.organism_classificationmedicine.diseaseNeuroprotective AgentsComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicineAndrographisRhodiolaFluorouracilPhytotherapyNeurogliaEpirubicinmedicine.drugPhytomedicine
researchProduct

Novel 3-Azaindolyl-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity

2012

Tumor growth and metastasis are highly associated with the overexpression of protein kinases (PKs) regulating cell growth, apoptosis resistance, and prolonged cell survival. This study describes novel azaindolyl-maleimides with significant inhibition of PKs, such as VEGFR, FLT-3, and GSK-3β which are related to carcinogenesis. Furthermore, these compounds exhibit high kinase selectivity and potent inhibition of angiogenesis and cell proliferation, offering versatile options in cancer treatment strategies.

AngiogenesisAngiogenesis InhibitorsApoptosisChick EmbryoPharmacologymedicine.disease_causeMetastasisMaleimidesNeovascularizationGlycogen Synthase Kinase 3Structure-Activity RelationshipNeoplasmsDrug DiscoveryHuman Umbilical Vein Endothelial Cellspolycyclic compoundsmedicineAnimalsHumansProtein kinase AProtein Kinase InhibitorsGSK3BCells CulturedCell ProliferationGlycogen Synthase Kinase 3 betaMolecular StructureNeovascularization PathologicKinaseChemistryCell growthCell CycleVascular Endothelial Growth Factor Receptor-3medicine.diseaseVascular Endothelial Growth Factor Receptor-2Growth Inhibitorsfms-Like Tyrosine Kinase 3Molecular Medicinemedicine.symptomCarcinogenesisJournal of Medicinal Chemistry
researchProduct

Cyclooxygenase inhibitors – current status and future prospects

2001

Prostaglandins are formed from arachidonic acid by the action of cyclooxygenase and subsequent downstream synthetases. Two closely related forms of the cyclooxygenase have been identified which are now known as COX-1 and COX-2. Both isoenzymes transform arachidonic acid to prostaglandins, but differ in their distribution and their physiological roles. Meanwhile, the responsible genes and their regulation have been clarified. COX-1, the pre-dominantly constitutive form of the enzyme, is expressed throughout the body and performs a number of homeostatic functions such as maintaining normal gastric mucosa and influencing renal blood flow and platelet aggregation. In contrast, the inducible for…

AngiogenesisInflammationPharmacologyStructure-Activity Relationshipchemistry.chemical_compoundIndometacinDrug DiscoverymedicineAnimalsHumansCyclooxygenase InhibitorsPharmacologyMolecular StructurebiologyAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryGeneral Medicinemedicine.diseasechemistryBiochemistryEnzyme inhibitorRheumatoid arthritisbiology.proteinArachidonic acidCyclooxygenasemedicine.symptomHomeostasisForecastingmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Synthesis and antioxidant evaluation of novel silybin analogues

2006

In this work, we evaluated the antioxidant properties of the eight novel silybin analogues for their capacity to scavenge free radicals including superoxide anion radicals and 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals in vitro. Compound 7d demonstrated an excellent antioxidant effect in scavenging superoxide anion free radical with an IC50 value of 26.5 microM, while the IC50 of quercetin (the reference compound) was 38.1 microM. Compounds 7b, 7e, 7h showed certain scavenging activities for both types of free radicals.

AnionsAntioxidantDPPHRadicalmedicine.medical_treatmentDrug Evaluation PreclinicalMedicinal chemistryAntioxidantsInhibitory Concentration 50chemistry.chemical_compoundPicratesSuperoxidesDrug DiscoverymedicineOrganic chemistryIC50PharmacologyDose-Response Relationship DrugSuperoxideBiphenyl CompoundsAnion radicalsFree Radical ScavengersGeneral MedicineIn vitroHydrazinesModels ChemicalchemistrySpectrophotometrySilybinQuercetinQuercetinSilymarinJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct